ARKRAY USA Launches PocketChem(TM)EZ Blood Glucose Monitoring System
Posted on: Monday, 16 July 2007, 09:13 CDT
MINNEAPOLIS, July 16 /PRNewswire/ -- ARKRAY USA, Inc. announced today that it has started to sell its PocketChem(TM)EZ Blood Glucose Monitoring System for people with diabetes. ARKRAY USA, Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market this system earlier in the year.
PocketChem(TM)EZ makes testing easy! This intuitive system gives results in 10 seconds, requires a 1 microliter sample size, and has a 250-count test memory with time and date stamp. The choice of palm or fingertip testing, combined with the ability to reapply blood within 10 seconds if the first drop is too small (double dosing), makes testing more comfortable. It also features a large, easy-to-read display for better viewing of test results.
"PocketChem EZ is a welcome new tool for diabetes self management. The small sample size and choice of palm or fingertip testing makes it easier for patients to test quickly, comfortably, and accurately," said Jonathan Chapman, President for ARKRAY USA, Inc. "This cost effective system is a significant extension of our Self Monitoring Blood Glucose portfolio."
About ARKRAY USA
ARKRAY USA, Inc. (http://www.arkrayusa.com/) is a leading healthcare company specializing in diagnostic products and medical devices at the point of care. ARKRAY develops, manufactures, and markets innovative diagnostic products and related medical devices used in managing chronic diseases such as diabetes, screening for acute conditions utilizing blood and urine diagnostics, and enhancing healthcare worker safety. The company's primary products include a broad line of blood glucose monitoring systems, safety lancets and lancing devices, as well as urine testing equipment and supplies. ARKRAY's focus is to improve today's technology to develop products that are even more convenient and safe.
ARKRAY USA, Inc.
CONTACT: Angela Howe, Marketing Manager of ARKRAY USA, Inc.,+1-952-646-3224, info@arkrayusa.com
Web site: http://www.arkrayusa.com/
Source: PRNewswire
Related Articles
- ARKRAY USA Receives FDA Clearance on GLUCOCARD(R) 01-mini Blood Glucose Monitoring System
- FDA Grants AMDL Clearance to Market the AMDL-ELISA DR-70(R) (FDP) Blood Test for Monitoring Colorectal Cancer
- Blood Test a Very Early Indicator of Type 2 Diabetes
- Blood Test Makes Diagnosing TB Faster and Easier
- GlycoMark Blood Test Included in Global Diabetes Care Guidelines As Emerging Technology
- MedApps D-PAL(TM) Remote Patient Monitoring System for Diabetes Cleared for Over-the-Counter Use By FDA
- All Major National Reference Laboratories Now Offer New GlycoMark Diabetes Blood Test to Complement Hemoglobin A1c Testing in Patients With Diabetes
- New Study Shows GlycoMark Blood Test is Most Effective Monitor of After-Meal Glucose Levels in Patients With Diabetes
- New Blood Test for Management of Osteoporosis Cleared By the FDA; Roche Diagnostics' Test Aids Physicians and Patients in Monitoring Disease
 |
 |
User Comments (0)
RSS Feeds